Summary:
If you have been diagnosed with generalized myasthenia gravis (gMG), you may be able to take part in a clinical research study.
The purpose of the Prevail Study is to evaluate the safety and effectiveness of an investigational study medication (ALXN1720) compared to placebo for reducing symptoms of gMG in adults 18 years of age or older. The Prevail Study is evaluating if the study medication may reduce gMG symptoms based on change from baseline on the Myasthenia Gravis Activities of Daily Living (MG-ADL) total score. The study medication and the placebo will be administered via subcutaneous injection on a weekly basis.
All participants who qualify will receive the study medication or a placebo, as well as study-related exams and study-related laboratory tests at no cost. Compensation for time and travel may also be available.
Eligible participants must:
- Be 18 years of age or older
- Have a documented diagnosis of myasthenia gravis
- Have symptoms that involve weakness of more than just the eyes: e.g., affecting speech, swallowing, breathing, arm or leg movements
- Not have had a thymectomy or other thymus surgery within the past 12 months
- Not have a tumor of the thymus that has not been treated
Other protocol-defined inclusion and exclusion criteria may apply.